The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

CEO Larry Ellison’s claims that artificial intelligence (AI) could help develop messenger RNA-based (mRNA) vaccines to cure ...

Moderna is testing a norovirus vaccine in a phase three trial. Results could be available as soon as this year.

Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat the highly contagious stomach virus.

Only 23 countries use climate data for health surveillance, says head of WMO, adding more collaboration needed ...

To get a sense of who is truly in control of Moderna, Inc. ( NASDAQ:MRNA ), it is important to understand the ownership structure of the business. With 69% stake, institutions possess the maximum ...

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...

With COVID-19 revenues now shrinking fast, Moderna chief executive Stéphane Bancel has taken the decision to rein in spending and reduce the number of active development programmes, which have ...

Moderna's chief executive, Stéphane Bancel, said the partnership will “prepare ourselves for the era of quantum computing, and ready our business for these game-changing technologies.” ...